HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sulfinpyrazone

HCID 5342
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
57-96-5
Standard SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
Molecular formula
C23H20N2O3S
Average molar mass
404.5 g/mol
Monoisotopic mass
404.11946368

Overview

Sulfinpyrazone is a sulfoxide and a member of pyrazolidines. It has a role as a uricosuric drug.

Names & identifiers

Preferred name
Sulfinpyrazone
IUPAC
4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dione
English name
(+/-)-Sulfinpyrazone
Molecular formula
C23H20N2O3S
Molecular weight
404.48

Names & synonyms

sulfinpyrazone57-96-5SulphinpyrazoneAnturaneAnturanDiphenylpyrazoneSulfoxyphenylpyrazolidineSulfinpyrazonAnturidinEnturenAnturanil1,2-Diphenyl-4-(2-(phenylsulfinyl)ethyl)pyrazolidine-3,5-dione
Show more names
g28315anturenenturang28,315
AnturanoUSAF GE-13SulfinpirazonaSulfinpyrazonum4-[2-(benzenesulfinyl)ethyl]-1,2-diphenylpyrazolidine-3,5-dioneDTXSID00236184-(Phenylsulfoxyethyl)-1,2-diphenyl-3,5-pyrazolidinedione1,2-Diphenyl-4-(2'-phenylsulfinethyl)-3,5-pyrazolidinedione

Database identifiers

CAS
57-96-5
PubChem CID
5342
DTXSID
DTXSID0023618
ChEMBL
CHEMBL832
ChEBI
CHEBI:9342
UNII
V6OFU47K3W
EC Number
200-357-4
Nikkaji
J1.384F

Properties

Computed structural propertiesFilling in

XLogP
2.3
Topological polar surface area
76.9 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
4
Rotatable bonds
6
Heavy atoms
29
Formal charge
0
Complexity
571

Experimental & physicochemical properties

LogP · 2 items

2.4

3.56

Color/FormWHITE TO OFF-WHITE
Solubility · 5 items

SOL IN ETHYL ACETATE, CHLOROFORM

SLIGHTLY SOL IN WATER, ALC, ETHER, MINERAL OILS

SLIGHTLY SOL IN FATS

1 G SOL IN 10 ML ACETONE & 10 ML 0.5 N NAOH

For more Solubility (Complete) data for SULFINPYRAZONE (6 total), please visit the HSDB record page.

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point · 4 items

136-137 °C

136-137 °C

MELTING POINT: 130-133 °C /D-FORM, L-FORM/

136 - 137 °C

Physical DescriptionSolid
Stability/Shelf LifeSTABLE TO LIGHT & AIR
Dissociation Constants · 2 items

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 70 reports by companies from 1 notifications to the ECHA C&L Inventory.

Hazard information

Other Safety InformationIMAP assessments - 3,5-Pyrazolidinedione, 1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]-: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxicology

Interactions · 3 items

...URICOSURIC ACTION /OF SULFINPYRAZONE/ IS ADDITIVE TO THAT OF PROBENECID & PHENYLBUTAZONE BUT IS MUTUALLY ANTAGONISTIC TO THAT OF SALICYLATES. ... POSSESSES ABILITY TO DISPLACE OTHER ORG ANIONS THAT ARE BOUND EXTENSIVELY TO PLASMA PROTEINS...THUS ALTERING THEIR DISTRIBUTION TO TISSUES & THEIR RENAL EXCRETION...

...SULFINPYRAZONE MAY POTENTIATE ACTIONS OF INSULIN & ORAL HYPOGLYCEMIC AGENTS...

SULFINPYRAZONE MAY DISPLACE SULFONAMIDES FROM PLASMA PROTEIN BINDING SITES...

Human Toxicity Excerpts · 2 items

HYPERSENSITIVITY REACTIONS, USUALLY A RASH WITH FEVER, DO OCCUR.../OCCASIONALLY/

SIDE EFFECTS INCL UPPER GI DISTURBANCES...&, RARELY, ANEMIA, LEUKOPENIA, AGRANULOCYTOSIS, & THROMBOCYTOPENIA.

Safety data

PPE
dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Chemistry & industry

Pharmacology

ATC Code · 2 items

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding98-99%
Pharmacodynamics · 1 item

Sulfinpyrazone's pharmacologic activity is the potentiation of the urinary excretion of uric acid. It is useful for reducing the blood urate levels in patients with chronic tophaceous gout and acute intermittent gout, and for promoting the resorption of tophi.

Mechanism of Action · 2 items

Sulfinpyrazone is an oral uricosuric agent (pyrazolone derivative) used to treat chronic or intermittent gouty arthritis. Sulfinpyrazone competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby facilitating urinary excretion of uric acid and decreasing plasma urate concentrations. This is likely done through inhibition of the urate anion transporter (hURAT1) as well as the human organic anion transporter 4 (hOAT4). Sulfinpyrazone is not intended for the treatment of acute attacks because it lacks therapeutically useful analgesic and anti-inflammatory effects. Sulfinpyrazone and its sulfide metabolite possess COX inhibitory effects. Sulfinpyrazone has also been shown to be a UDP-glucuronsyltransferase inhibitor and a very potent CYP2C9 inhibitor. Sulfinpyrazone is also known to be a cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor as well as an inhibitor of several multridrug resistance proteins (MRPs).

...IN SUFFICIENT DOSAGE IS POTENT INHIBITOR OF RENAL TUBULAR REABSORPTION OF URIC ACID. ...SMALL DOSES MAY REDUCE EXCRETION...PRESUMABLY BY INHIBITING SECRETORY BUT NOT REABSORPTIVE TRANSPORT. BY COMPETITIVE INHIBITION...REDUCES RENAL TUBULAR SECRETION OF OTHER ORG ANIONS...AS PAH /PARA-AMINOHIPPURIC/ & SALICYLIC ACID.

Biological Half-LifeApproximately 4-6 hours
Metabolism/Metabolites · 3 items

MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS N1-P-HYDROXYPHENYL METABOLITE...

.../IN RAT/ 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE.

Related reactions

6 records
New reaction record
HRID 156978 reaction equation
HRID 156978As product
HRID 833034 reaction equation
HRID 833034As reactant
HRID 1577634 reaction equation
HRID 1577634As product
HRID 1577636 reaction equation
HRID 1577636As product
HRID 1577637 reaction equation
HRID 1577637As product
HRID 1719691 reaction equation
HRID 1719691As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

3.25

PKA: 2.8

Collision Cross Section · 2 items

193.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

193.18 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Other Experimental Properties · 3 items

CRYSTALS FROM CHLOROFORM & HEPTANE; CRYSTALS FROM ETHANOL /D-FORM/; CRYSTALS /L-FORM/

SPECIFIC OPTICAL ROTATION: +67.1 DEG @ 22 °C/D (C= 2.04 IN ETHANOL); +109.3 DEG @ 25 °C/D (C= 0.5 IN CHLOROFORM) /D-/

SPECIFIC OPTICAL ROTATION: -64.2 DEG @ 23 °C/D (C= 2.14 IN ETHANOL); -104.5 DEG @ 26 °C/D (C= 0.5 IN CHLOROFORM) /L-/

Physicochemical properties

Melting point
136 · 136-137°
Boiling point
590.8 · 590.8±42.0 °C(Predicted)
Density
1.189 · 1.1890 (rough estimate)
refractive index
1.636 · 1.6360 (estimate)
storage temp.
Sealed in dry,Room Temperature
solubility
Very slightly soluble in water, sparingly soluble in ethanol (96 per cent). It dissolves in dilute solutions of alkali hydroxides.
form
Solid
pka
2.8 · pKa 2.8(H2O t = RT I undefined) (Uncertain)
color
Off-White to Light Brown
Water Solubility
2.601 g/L · 2.601g/L(22 ºC)
Major Application
cleaning productscosmeticsfood and beveragesforensics and toxicologypersonal carepharmaceutical (small molecule)veterinary
InChI
1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
InChIKey
MBGGBVCUIVRRBF-UHFFFAOYSA-N
SMILES
O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4
CAS DataBase Reference
57 · 57-96-5(CAS DataBase Reference)
FDA UNII
6 OFU47K3W · V6OFU47K3W
NIST Chemistry Reference
Sulfinpyrazone(57-96-5)
ATC code
4 AB02 · M04AB02
UNSPSC Code
41116107 · 41116107
NACRES
24 · NA.24
Protein binding
98 % · 98%
Excreted unchanged in urine
22 · 22-42%
Volume of distribution
0.06 · 0.06(L/kg)
Biological half-life
2 · 2-4 / Unchanged
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302
Precautionary statements
264 · P264-P270-P301+P312-P501
PPE
95 · dust mask type N95 (US), Eyeshields, Faceshields, Gloves
Hazard Codes
Xn
Risk Statements
22 · 22
Safety Statements
36 · 36
WGK Germany
3 · 3
RTECS
8575000 · UQ8575000
HS Code
2933194350 · 2933194350
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 Oral · Acute Tox. 4 Oral
Hazardous Substances Data
57 · 57-96-5(Hazardous Substances Data)
wgk
3
rtecs
UQ8575000
hs_code
2933194350
risk_code
22
Signal word
Warning
Symbol(GHS)
GHS07
hazard_code
Xn
safety_code
36
Storage Class
11 - Combustible Solids
Hazard statements
H302
Hazard Classifications
Acute Tox. 4 Oral
Precautionary statements
P264-P270-P301+P312-P501
Hazardous Substances Data
57-96-5(Hazardous Substances Data)

Sulfinpyrazone has known human metabolites that include Sulfinpyrazone sulfone.

MeSH Pharmacological ClassificationGout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.
Absorption, Distribution and Excretion · 5 items

...WELL ABSORBED AFTER ORAL ADMIN. ...BOUND TO PLASMA PROTEINS...98-99%. T/2... IN PLASMA AFTER IV INJECTION IS ABOUT 3 HR. AFTER ORAL ADMIN...URICOSURIC EFFECT MAY PERSIST FOR...10 HR. ALTHOUGH LITTLE...IS AVAILABLE FOR FILTRATION @ GLOMERULUS, IT IS SECRETED BY PROXIMAL TUBULE & UNDERGOES LITTLE PASSIVE BACK DIFFUSION...

APPROX HALF OF ORALLY ADMIN DOSE APPEARS IN URINE WITHIN 24 HR. MOST OF DRUG (90%) IN URINE IS UNCHANGED; REMAINDER IS ELIMINATED AS...METABOLITE...

...RAPIDLY EXCRETED IN MAN, TOGETHER WITH P-HYDROXYLATED METABOLITE. PLASMA T/2...IN RATS...16.2 HR, &...18% OF IP DOSE...WAS EXCRETED INTO URINE. PLASMA T/2 IN MAN...BETWEEN 1 & 3 HR. MAIN ROUTE OF ELIMINATION IN RAT...FECES (68% OF DOSE)...CONSIDERABLE PORTION...EXCRETED IN BILE WAS REABSORBED FROM INTESTINAL TRACT.

...SULFINPYRAZONE...IS EXCRETED IN URINE OF RATS TO ONLY A SMALL EXTENT. ... CLEARED FROM CIRCULATION MAINLY THROUGH BILE...NO EVIDENCE OF ENTERO-HEPATIC CIRCULATION MECHANISM.

UNCHANGED DRUG /IN RAT/ WAS PRINCIPAL EXCRETION PRODUCT & ONLY 28%...IN URINE & 24%...IN FECES & BILE WAS FOUND AS P-HYDROXYSULFINPYRAZOLE. FAILURE OF RAT TO EXCRETE A HIGH PROPORTION OF THE DRUG IN URINE MAY BE RELATED TO ITS LACK OF URICOSURIC PROPERTIES IN THIS SPECIES.

Cellular LocationsCytoplasm

Uses & manufacturing

UsesMEDICATION
Methods of Manufacturing · 2 items

SYNTHESIS: PFISTER, HAFLIGER, HELV CHIM ACTA 44, 232 (1961).

[2-(PHENYLSULFINYL)ETHYL]MALONIC ACID DIETHYL ESTER IS CONDENSED WITH HYDRAZOBENZENE WITH AID OF SOLN OF SODIUM ETHOXIDE IN ABSOLUTE ETHANOL. ... /ADDN/ XYLENE & HEATING @...130 DEG...ETHANOL...IS REMOVED. SULFINPYRAZONE IS ISOLATED BY SOLVENT EXTRACTION...& RECRYSTALLIZED FROM ETHANOL. US PATENT 2,700,671.

Formulations/PreparationsANTURANE (GEIGY). ORAL: CAPSULES 200 MG; TABLETS 100 MG.
Applications · 6 items

DescriptionSulfinpyrazone is soluble in alkaline solutions. Its synthesis is similar to that of phenylbutazone (Fig. 36.33). It produces its uricosuric effect in a manner similar to that of probenecid. A dose of 35 mg produces a uricosuric effect equivalent to that produced by 100 mg of probenecid, whereas 400 mg/day of sulfinpyrazone produces an effect comparable to that obtained with doses of 1.5 to 2 g of probenecid. It also possesses, not surprisingly, some of the properties of phenylbutazone. It is an inhibitor of human platelet prostaglandin synthesis at the cyclooxygenase step, resulting in a decrease in platelet release and a reduction in platelet aggregation. This antiplatelet effect suggests a role for sulfinpyrazone in reducing the incidence of sudden death, which can occur in the first year following a myocardial infarction; however, it lacks the analgetic and anti-inflammatory effects of phenylbutazone.

DescriptionSulfinpyrazone is a uricosuric agent that competitively inhibits uric acid reabsorption in kidney proximal tubules, which is a key mechanism targeted in the treatment of gout. It can also inhibit degranulation of platelets, reducing the release of ADP and thromboxane and diminishing platelet aggregation.

UsesAs an anti-inflammatory and uricosuric agent, its side effects were severe enough to preclude its continuous use in the treatment of chronic gout. Evaluation of several chemical congeners indicated that the phenylthioethyl analog of phenylbutazone had promising anti-inflammatory and uricosuric activity. A metabolite, the sulfoxide pyrazone, exhibited enhanced uricosuric activity. Interestingly, the corresponding sulfone does not appear to be a metabolite. Sulfinpyrazone lacks the clinically striking anti-inflammatory and analgesic properties of phenylbutazone.

UsesSulfinpyrazone is used in the treatment of gout acting as a uricosuric medication.

UsesSulfinpyrazone is used upon exactly the same indications as phenylbutazone.

General DescriptionSulfinpyrazone (Anturane) produces its uricosuric action ina similar manner to that of probenecid and is indicated forthe treatment of chronic and recurrent gouty arthritis. It iswell absorbed with approximately 50% of the administereddose excreted as unchanged drug into the renal tubules. Therest of the drug is primarily metabolized via CYP2C9 intothe corresponding sulfide and sulfone metabolites, thus itcan potentiate the anticoagulant effect of warfarin.

Upstream & downstream products

Upstream raw materials

Sodiumperoxomonosulphuric acid1,2-diphenyl-4-(2-phenylthioethyl)pyrazolidine-3,5-dioneSodium bicarbonateEthyl acetateSodium bisulfiteAcetic acidToluene

Additional notes

DefinitionChEBI: Sulfinpyrazone is a sulfoxide and a member of pyrazolidines. It has a role as a uricosuric drug.